Background: Primary open angle glaucoma (POAG) is the most common form of glaucoma, with a multifactorial etiology that results in retinal ganglion cell death and loss of vision. In this study, we assessed the effects of myricetin on the trabecular meshwork cells in POAG. Methods: In the in-vivo model, glaucoma was induced in Sprague-Dawley rats by injecting hyaluronic acid into the anterior chamber of the eye (every week for six-weeks). Treatment group rats were administered myricetin (25, 50 or 100 mg/ kg body weight via oral gavage) each day for of six weeks. Results: POAG TM cells exposed to myricetin (25, 50 or 100 μM) exhibited significantly lowered reactive oxidative species (ROS) levels and lipid peroxidation products. The expressions of transforming growth factors (TGFβ1/ β2), vascular endothelial growth factor, and senescence markers (senescence associated-β-galactosidase, cyclindependent kinase inhibitors-p16 and p21) were substantially down-regulated in POAG TM cells exposed to myricetin. Myricetin effectively prevented IOP elevation in glaucoma-induced rats and decreased inflammatory cytokines (IL-1α, IL-1β, IL-6, Il-8, TNF-α) in the aqueous humor and POAG TM cells of glaucoma-induced rats. Conclusion: The observations of the study illustrate the protective effects of myricetin in glaucomatous TM cells.
INTRODUCTION
Glaucoma constitutes a group of optic neuropathies that can cause loss of vision and gradual loss of retinal ganglion cells (RGC) [1] .
Primary open angle glaucoma (POAG), one of the leading causes of visual impairment worldwide, is the most common form of glaucoma. POAG is a multifactorial disease with a complex, unknown etiology that causes irreversible damage to the optic nerve. The principal factor involved in the onset and progression of POAG is raised intraocular pressure (IOP) [2] . RGCs are highly vulnerable to damage caused by this abnormally raised IOP [3] . IOP is affected by the balance of aqueous humor (AH) secretion by the ciliary body, and outflow of AH into the venous circulation via the trabecular meshwork (TM), a specialised optic tissue [4, 5] . In POAG, the TM exhibits considerable abnormal changes including decreased cellularity, accumulation of extracellular matrix (ECM) components, and changes in the actin cytoskeleton [6, 7] .
Reactive oxygen species (ROS)-induced oxidative stress has been reported to be critical in the pathology of increased IOP in POAG [8] [9] [10] . ROS including superoxide anions and H 2 O 2 have been observed in AH. Izzotti et al. [11] reported that ROS increase outflow resistance in the anterior chamber [12] . Several other clinical studies have also described increased lipid peroxidation products in the TM cells of glaucomatous patients, suggesting high oxidative stress as a major factor in the pathophysiology of glaucoma [13] [14] [15] [16] . ROS are known to be associated with signalling pathways that influence the expressions of many cytokines and growth factors, such as transforming growth factor βs (TGFβs) [17] .
Some pro-inflammatory and fibrogenic factors have also been detected in the aqueous humor, reflecting the ongoing inflammation associated with glaucoma [18, 19] . In glaucoma, pro-inflammatory cytokines secreted by macrophages include IL-1β, IL-6, and TNF-α.
These cytokines cause further remodelling of the ECM that results in altered cytoskeletal interactions in TM cells [20] .
In aging and glaucomatous TM cells, elevated cellular oxidative stress is found to activate senescence markers such as cyclindependent kinase (CDK) inhibitors p16 and p21 [21] . Several studies have reported the accumulation of senescence cells in POAG [22, 23] suggesting the role of oxidative stress in aging [24, 25] . The use of antioxidants is critical to combat the oxidative stressors caused by the production of ROS and for the maintenance of homeostasis. Under conditions of ROS overproduction, supplementation with compounds of a high antioxidant potential is immensely valuable. Studies have shown that antioxidants could offer protection against the ROS-induced pathogenesis seen in glaucoma [26] . Previous treatment with the antioxidant compound resveratrol was found to effectively reduce levels of ROS and inflammatory markers within the eye [23] .
Flavonoids are naturally occurring polyphenolic compounds widely present in fruits and vegetables [27] . Flavonoids possess several bioactive properties including anti-oxidant, anti-inflammatory, and neuroprotective effects [28] . Studies have reported that flavonoids can reduce oxidative stress [28, 29] and improve ocular blood flow in POAG [30] . Myricetin, (3, 5, 7, 3 ' ,4' ,5'-hexahydroxyflavone) is present in apples, oranges, berries, and vegetables. It has been found to possess antioxidant, anti-tumor, anti-inflammatory, neuroprotective [31, 32] , and antibacterial properties [33, 34] . Myricetin treatment was also observed to inhibit hyperglycemia and decrease serum lipid levels in patients [31, 35] . In this study, we evaluated the effect of myricetin in glaucomatous TM cells. Western blot analysis Final PCR products were separated on 2% agarose gel and bands were stained with 0.05% ethidium bromide. Final intensities were analyzed using the Bio-Gel imagery apparatus (Bio-Rad, USA). 
MATERIALS AND METHODS

Chemicals and antibodies
In-vivo studies
Study design
The rats were randomly separated into five groups (n=12/group). To induce glaucoma, rats were anesthetized with ketamine (100mg/ mL) and xylazine (20mg/mL), and one drop of 0.5% proparacaine hydrochloride was applied to each eye. IOP was measured immediately following induction of anaesthesia. Following previous protocols described by Moreno et 
RESULTS
Myricetin reduced the ROS-induced oxidative stress in the POAG TM cells Several studies have also reported significantly elevated protein carbonyl levels in glaucoma [58] [59] [60] , and that an oxidant/antioxidant imbalance can increase the levels of ROSinduced TM damage [61, 62] . Our study found that glaucoma subjects had a 2-fold decrease in SOD activity (specify 'the activity'). SOD is a chief antioxidant enzyme that protects against oxidative stress [15, 63] . stress-induced neurodegeneration [15, 64] .
Animal studies of IOP lowering drops such as Latanoprost demonstrate that while these medications can lower IOP, they do not reverse or improve the oxidative stress or damage a way that can result in elevated IOP [41] .
Significantly (p<0.05) elevated ROS levels were seen in hyaluronic acid-treated rats compared to normal controls ( Figure 6 ). Increased ROS levels were seen with a concurrent rise in IOP.
Myricetin at all three tested doses significantly decreased the level of ROS detected in the AH, with a maximal IOP lowering effect seen at the 100mg dose. ROS levels were reduced to 14.02% on treatment with 100 mg myricetin.
Myricetin reduced inflammatory cytokines in the AH of hyaluronic acid-treated rats [7, 42] . Currently therapies primarily lower IOP through the use of medications such as prostaglandin analogues, beta-blockers, alphaagonists, and carbonic anhydrase inhibitors. While these drugs can effectively lower IOP, they do not offer complete protection. Some patients can also experience vision loss despite normal IOP [43] . As such, the need for the identification and development of novel drugs that can target mechanisms involved in the pathogenesis of POAG are highly valuable [44, 45] .
It is well documented that oxidative stress damages biomolecules via peroxidation.
Previous studies have shown that oxidative stress can elevate IOP, and is involved in the pathogenesis of glaucoma [8, 9, 46] 100 µM of myricetin was found to significantly down-regulate overall expression levels, respectively reducing VEGF, TGF-β1, and TGF-β2 by 1.6-fold, 1.7-fold, and 1.5-fold.
Myricetin effectively reduced IOP following glaucoma induction in rats
Raised intraocular pressure (IOP) is a major risk factor for POAG [40] . Following the experimental induction of glaucoma, a marked (p<0.05) increase in IOP was observed over 6 weeks ( Figure 5 ). IOP in animals treated with oral myricetin (25, 50 or 100 mg) was found to be considerably lower than the IOP of glaucoma control rats over the period of study, although a noticeable increase was seen between the normal controls and myricetin-treated groups.
IOP increased from 17mmHg in the 1 st week to 35.5mmHg in the 6 th week in the glaucoma group. IOP decreased from 35.5mmHg to 10mmHg on treatment with 100 mg myricetin.
These results indicate the efficacy of myricetin in lowering IOP, which is of immense clinical value in the management of glaucoma.
Effects of myricetin on ROS levels in the AH of hyaluronic acid-treated rats ROS levels in the AH can affect TM cells in Inflammation is known to be increased in POAG [23] . Cytokines, including IL-1α, IL-1β, IL-6, and TNF-α have been shown to be associated in the pathogenesis of POAG [66] . Numerous studies have reported these cytokines in the AH and anterior chamber tissues of POAG patients [67, 68] . ROS-mediated oxidative stress induces abnormal cell signalling [10, 71] . ROS has been found to activate growth factors such as TGF-β that, in turn, can induce oxidative stress leading to further cellular damage [71, 72] . Raised VEGF levels have been found in glaucomatous TM cells [73] . Studies have shown that cultured human TM cells exposed to TGF-β1/2 exhibit phenotypic changes [6, 74] and upregulation of ECM proteins, such as α-SM-actin, which are associated with glaucoma pathogenesis [9, 75] .
In keeping with previous studies, we found substantially elevated expressions of TGF-β1/2
and VEGF in the POAG group. These TM cell changes suggest that raised oxidative stress levels could be a contributing factor to the upregulation of these inflammatory markers.
Previous in vitro studies have reported that myricetin exposure at various concentrations 
CONCLUSION
The results of our study suggest that myricetin is efficacious in preventing oxidative stress- 
